Australia's most trusted
source of pharma news
Wednesday, 18 March 2026
Posted 18 March 2026 PM
Sydney-based Immutep has suffered a severe setback, opting to discontinue a phase 3 trial of its flagship product Eftilagimod Alfa due to futility.
It comes just three months after the company signed an exclusive licensing deal for the first-in-class immunotherapy hopeful, which would have amounted to more than half-a-billion-dollars if all milestones had been met.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.